DK3149000T3 - Krystallinsk tosylatsalt af en pi3k-delta-selektiv inhibitor til anvendelse i farmaceutiske formuleringer - Google Patents

Krystallinsk tosylatsalt af en pi3k-delta-selektiv inhibitor til anvendelse i farmaceutiske formuleringer Download PDF

Info

Publication number
DK3149000T3
DK3149000T3 DK15733532.4T DK15733532T DK3149000T3 DK 3149000 T3 DK3149000 T3 DK 3149000T3 DK 15733532 T DK15733532 T DK 15733532T DK 3149000 T3 DK3149000 T3 DK 3149000T3
Authority
DK
Denmark
Prior art keywords
crystallinic
pharmaceutical formulations
selective inhibitor
tosylate salt
pi3k delta
Prior art date
Application number
DK15733532.4T
Other languages
English (en)
Inventor
Swaroop Kumar Venkata Satya Vakkalanka
Original Assignee
Rhizen Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals S A filed Critical Rhizen Pharmaceuticals S A
Application granted granted Critical
Publication of DK3149000T3 publication Critical patent/DK3149000T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK15733532.4T 2014-05-27 2015-05-26 Krystallinsk tosylatsalt af en pi3k-delta-selektiv inhibitor til anvendelse i farmaceutiske formuleringer DK3149000T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2597CH2014 2014-05-27
IN2596CH2014 2014-05-27
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Publications (1)

Publication Number Publication Date
DK3149000T3 true DK3149000T3 (da) 2021-08-30

Family

ID=53499042

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15733532.4T DK3149000T3 (da) 2014-05-27 2015-05-26 Krystallinsk tosylatsalt af en pi3k-delta-selektiv inhibitor til anvendelse i farmaceutiske formuleringer

Country Status (21)

Country Link
US (4) US9969740B2 (da)
EP (2) EP3149000B1 (da)
JP (3) JP6987501B2 (da)
KR (1) KR20170007480A (da)
CN (2) CN106661030B (da)
AU (1) AU2015265542B2 (da)
BR (1) BR112016027674A2 (da)
CA (1) CA2949932C (da)
CY (1) CY1124316T1 (da)
DK (1) DK3149000T3 (da)
EA (1) EA032506B1 (da)
ES (1) ES2880999T3 (da)
HR (1) HRP20211151T1 (da)
HU (1) HUE054916T2 (da)
IL (1) IL249058B2 (da)
LT (1) LT3149000T (da)
PL (1) PL3149000T3 (da)
PT (1) PT3149000T (da)
RS (1) RS62136B1 (da)
SI (1) SI3149000T1 (da)
WO (1) WO2015181728A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3149000T1 (sl) * 2014-05-27 2021-09-30 Rhizen Pharmaceuticals S.A. Kristalinična tosilatna sol selektivnega inhibitorja PI3K delta za uporabo v farmacevtskih oblikah
EA201892284A1 (ru) 2016-05-27 2019-08-30 Тг Терапьютикс, Инк. Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств
BR112019004185A2 (pt) 2016-09-09 2019-09-03 Lab Francais Du Fractionnement combinação de um anticorpo anti-cd20, inibidor de pi3-quinase-delta inibidor e anticorpo anti-pd-1 ou anti-pd-l1 para tratamento de cânceres hematológicos
JP2022540466A (ja) 2019-07-15 2022-09-15 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 非晶質ウムブラリシブモノトシレート
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1939203E (pt) * 2000-04-25 2015-02-04 Icos Corp Inibidores da isoforma delta da fosfatidil-inositol 3-quinase humana
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
CN104042618B (zh) 2008-11-13 2018-02-16 吉利德卡利斯托加公司 恶性血液病的治疗
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
EA201101507A1 (ru) 2009-04-20 2012-05-30 Гилеад Калистога Ллс. Способы лечения солидных опухолей
SI2870157T1 (en) * 2012-07-04 2018-02-28 Rhizen Pharmaceuticals S.A. SELECTIVE PI3K-DELTA INHIBITORS
SI3149000T1 (sl) * 2014-05-27 2021-09-30 Rhizen Pharmaceuticals S.A. Kristalinična tosilatna sol selektivnega inhibitorja PI3K delta za uporabo v farmacevtskih oblikah

Also Published As

Publication number Publication date
US10414773B2 (en) 2019-09-17
CA2949932C (en) 2021-08-10
JP2022082680A (ja) 2022-06-02
BR112016027674A2 (pt) 2017-08-15
CN111635406A (zh) 2020-09-08
SI3149000T1 (sl) 2021-09-30
LT3149000T (lt) 2021-09-10
US20210269446A1 (en) 2021-09-02
EP3149000B1 (en) 2021-06-30
US20190382411A1 (en) 2019-12-19
JP2020122022A (ja) 2020-08-13
EP3149000A1 (en) 2017-04-05
EP3971188A1 (en) 2022-03-23
US10947244B2 (en) 2021-03-16
ES2880999T3 (es) 2021-11-26
US9969740B2 (en) 2018-05-15
HUE054916T2 (hu) 2021-10-28
PT3149000T (pt) 2021-07-27
IL249058A0 (en) 2017-01-31
AU2015265542A1 (en) 2016-12-08
PL3149000T3 (pl) 2021-11-02
WO2015181728A1 (en) 2015-12-03
IL249058B2 (en) 2023-03-01
RS62136B1 (sr) 2021-08-31
CA2949932A1 (en) 2015-12-03
CN106661030B (zh) 2020-06-30
EA032506B1 (ru) 2019-06-28
JP2017516785A (ja) 2017-06-22
US20190016725A1 (en) 2019-01-17
KR20170007480A (ko) 2017-01-18
US20170121336A1 (en) 2017-05-04
CY1124316T1 (el) 2022-07-22
CN106661030A (zh) 2017-05-10
AU2015265542B2 (en) 2019-05-09
EA201692255A1 (ru) 2017-04-28
HRP20211151T1 (hr) 2021-10-15
JP6987501B2 (ja) 2022-01-05
IL249058B (en) 2022-11-01

Similar Documents

Publication Publication Date Title
DK3149000T3 (da) Krystallinsk tosylatsalt af en pi3k-delta-selektiv inhibitor til anvendelse i farmaceutiske formuleringer
HK1248229A1 (zh) Pi3k抑制劑的鹽及其製備方法
DK3149001T3 (da) Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK3139904T3 (da) Formulering af fedtopløselig vitamin
HK1232227A1 (zh) 作為 抑制劑的喹嗪酮衍生物
DK3534885T3 (da) Farnesyltransferase-inhibitorer til anvendelse i behandling af kræft
HK1250161B (zh) 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途
DK3286190T3 (da) Farmaceutiske saltformer af en inhibitor af semicarbazid-sensitiv aminoxidase (ssao)
DK3226888T3 (da) Administration af en selektiv inhibitor af il-6-trans-signalering
DK3233054T3 (da) Formuleringer af en PI3K/MTOR-hæmmer til intravenøs administration
DK3294288T3 (da) Inhibitorer af replikation af humant papillomavirus
PT3224253T (pt) Derivados do bis(sulfonamida) e sua utilização como inibidores de mpges
CO6900155A2 (es) Composiciones estables y métodos para su preparación
CO6920267A2 (es) Cimbra autolanzable para plataformas portuarias